Literature DB >> 17850190

Prolonged in vivo gene silencing by electroporation-mediated plasmid delivery of small interfering RNA.

Daniël Eefting1, Jos M Grimbergen, Margreet R de Vries, Vincent van Weel, Eric L Kaijzel, Ivo Que, Randall T Moon, Clemens W Löwik, J Hajo van Bockel, Paul H A Quax.   

Abstract

For the successful application of RNA interference in vivo, it is desired to achieve (local) delivery of small interfering RNAs (siRNAs) and long-term gene silencing. Nonviral electrodelivery is suitable to obtain local and prolonged expression of transgenes. By intramuscular electrodelivery of a plasmid in which two opposing human polymerase III promoters (H1 and U6) drive the expression of siRNA constructs that form functional double-stranded siRNAs, in combination with in vivo bioluminescence imaging, we were able to knock down exogenous delivered luciferase for at least 100 days in murine calf muscles. This effect was sequence specific, because scrambled siRNA had no effect. Moreover, we were able to demonstrate in vivo reduction of endogenous TLR4 expression for at least 1 week, using a similar vector expressing an siRNA for TLR4 in the muscle. In this study, we demonstrate that in vivo suppression of both endogenous (for at least 1 week) and introduced genes (>100 days) is feasible via plasmid-driven siRNA expression after electroporation-mediated intramuscular gene transfer. With this approach the short-term effect of oligonucleotides and the drawbacks of viral gene delivery, like immunological responses, could be circumvented. Therefore, this application of RNA interference is a useful tool with which to investigate gene function and might be promising as a therapeutic tool for locally acting diseases such as restenosis or tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850190     DOI: 10.1089/hum.2006.176

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

Review 1.  Gene electrotransfer: from biophysical mechanisms to in vivo applications : Part 2 - In vivo developments and present clinical applications.

Authors:  Jean-Michel Escoffre; Chloé Mauroy; Thomas Portet; Luc Wasungu; Aurelie Paganin-Gioanni; Muriel Golzio; Justin Teissié; Marie-Pierre Rols
Journal:  Biophys Rev       Date:  2009-11-10

Review 2.  Multimodality imaging of RNA interference.

Authors:  T R Nayak; L K Krasteva; W Cai
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

3.  Electroporation optimization to deliver plasmid DNA into dental follicle cells.

Authors:  Shaomian Yao; Samir Rana; Dawen Liu; Gary E Wise
Journal:  Biotechnol J       Date:  2009-10       Impact factor: 4.677

Review 4.  Merging molecular imaging and RNA interference: early experience in live animals.

Authors:  Alexei A Bogdanov
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

Review 5.  Recent advances in gene therapy for atrial fibrillation.

Authors:  Shin Yoo; Gail Elizabeth Geist; Anna Pfenniger; Markus Rottmann; Rishi Arora
Journal:  J Cardiovasc Electrophysiol       Date:  2021-07-06       Impact factor: 2.942

6.  The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes.

Authors:  Pascal Bus; Marion Scharpfenecker; Priscilla Van Der Wilk; Ron Wolterbeek; Jan A Bruijn; Hans J Baelde
Journal:  Diabetologia       Date:  2017-06-15       Impact factor: 10.122

7.  The VEGF Inhibitor Soluble Fms-like Tyrosine Kinase 1 Does Not Promote AKI-to-CKD Transition.

Authors:  Cleo C L van Aanhold; Angela Koudijs; Kyra L Dijkstra; Ron Wolterbeek; Jan A Bruijn; Cees van Kooten; Hans J Baelde
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.